You are here

• Home
• Therapy Areas
• Respiratory/Inflammation

• A phase II, double-blind, placebo-controlled, randomised, 6-way cross-over, single-dose study to investigate the local and systemic effects of 3 doses of inhaled AZD3199 (a β2-agonist) compared to formoterol in asthmatic patients

Disease

asthma

Drug Name

AZD3199

Generic Name

AZD3199

Sponsor

AstraZeneca

Drug Status

Discontinued

Phase

II

Start Date

Aug 11, 2008

Study Name

D0570C00007

Study Id

D0570C00007

ClinicalTrials.gov ID

NCT00736489

Recruiting Status

Closed

Protocol Status

Not Available

Report

Apr 9, 2009

• D0570C00007.pdf (145 KB)

Page tools

• Print
• Bookmark this page